On Thursday, Shares of Broadcom Corporation (NASDAQ:BRCM), lost -1.51% to $49.71.
Broadcom Corporation, declared a series of Memorandum of Understanding (MOU) agreements with several Chinese companies, counting H3C, Inspur and StarTimes. The signing of these agreements at Broadcom’s annual Asia Media Summit reflect the company’s ongoing commitment to expand planned relationships in the region and drive further innovation in home entertainment and the digital home. For more news, visit Broadcom’s Newsroom.
“It’s an exciting time for the China electronics market as it transitions from a manufacturing base to a global leader in design and development,” said Michael Hurlston, Broadcom Executive Vice President of Worldwide Sales. “This fast-growing and evolving industry represents an important element in our ongoing strategy for continued growth in existing markets and diversification into new areas. We’re thrilled to work with the region’s leading organizations in driving innovation forward.”
Broadcom Corporation provides semiconductor solutions for wired and wireless communications. Its products offer voice, video, data, and multimedia connectivity in the home, office, and mobile environments.
Shares of Horizon Pharma PLC (NASDAQ:HZNP), inclined -6.65% to $32.73, during its last trading session.
Horizon Pharma, declared its second-quarter 2015 financial results.
“We delivered exceptionally strong performance in the second quarter and through the first half of the year,” said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. “Our results significantly beat expectations on net sales, adjusted EBITDA and adjusted diluted earnings per share. In addition, we’re generating strong adjusted operating cash flow and we’re well positioned to deliver on our recently raised full-year 2015 net sales and adjusted EBITDA guidance.”
Second-quarter 2015 net sales of $172.8 million raised 161 percent. This was driven by strong growth in each of Horizon’s business units: primary care, orphan and specialty, in addition to the addition of new medicines to the primary care and orphan business units.
Primary Care Business Unit: Second-quarter DUEXIS sales of $44.2 million raised 148 percent as contrast to the second quarter of 2014, driven by accelerating prescription growth. In the second quarter, VIMOVO sales were $39.8 million and PENNSAID 2% sales were $29.4 million. Total prescriptions accelerated across all three medicines in the primary care business unit driven by their differentiated clinical benefits, strong sales and marketing execution and raised access to Horizon’s Prescriptions-Made-Easy™, or PME, program. Total prescriptions for DUEXIS, VIMOVO and PENNSAID 2% raised 68 percent, 52 percent and 142 percent, respectively, as contrast to the first quarter of 2015.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
Finally, Royal Gold, Inc USA) (NASDAQ:RGLD), ended its last trade with 0.29% gain, and closed at $49.16.
Royal Gold, reported net income attributable to Royal Gold stockholders (“net income”) of $52.0 million, or $0.80 per basic and diluted share, on annual revenue of $278.0 million in fiscal 2015 (ended June 30), contrast with net income of $62.6 million, or $0.96 per basic and diluted share, on revenue of $237.2 million in fiscal 2014. The Company also reports record operating cash flow of $192.1 million for fiscal 2015 contrast with $147.2 million in fiscal 2014. The average gold price in fiscal 2015 was $1,224 per ounce, down 6% from $1,296 per ounce in fiscal 2014.
Fiscal 2015 Financial Highlights:
- Revenue of $278 million, an enhance of 17% over fiscal 2014
- Record operating cash flow of $192.1 million, an enhance of 31% over fiscal 2014
- Record volume of 227,100 Gold Equivalent Ounces (“GEO’s”) 1
- Adjusted EBITDA2 of $3.33 per basic share, or 78% of revenue
- Cash dividends of $56.1 million, 14successive years of increasing dividends
Royal Gold, Inc., together with its auxiliaries, acquires and manages precious metals royalties, metal streams, and similar interests. It focuses on acquiring royalty interests or to finance projects that are in production or in development stage in exchange for royalty interests.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
